prospective study for treatment strategies after the decision of allogeneic HSCT in patients with MDS (KSGCT1303/ MDS-prospective)

prospective study for treatment strategies after the decision of allogeneic HSCT in patients with MDS (KSGCT1303/ MDS-prospective) - KSGCT1303 / MDS-prospective

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000013144

Enrollment

100

Registered

2014-02-13

Start date

2014-02-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myelodysplastic syndromes (MDS)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with MDS according to FAB classification or AML secondary to MDS. 2.Patients who decided to undergo HSCT. 3.Patients who are more than 16 years old. 4. Patients who had received any kind of prior treatment other than HSCT will be included. Any kind of HSCT and post-transplantation treatment are allowed.

Exclusion criteria

Exclusion criteria: 1.Patients with treatment-related MDS. 2.Patients who had received HSCT. 3.Patients who do not provide written informed consent.

Design outcomes

Primary

Measure	Time frame
1-year overall survival after the registration	—

Secondary

Measure	Time frame
1)the rate of patients who actually receive HSCT within 1 year after the registration 2)1-year overall survival after HSCT 3)1-year progression-free survival after HSCT 4)non-relapse mortality after HSCT, relapse rate after HSCT	—

Countries

Japan

Contacts

Public ContactShinichi Kako

Kanto Study Group for Cell Therapy Trial Office

shinichikako@asahi-net.email.ne.jp048-647-2111

Outcome results